Brian I. Rini, MD

Articles

Dr. Rini on the Results of an Exploratory Analysis of the IMmotion151 Trial in mRCC

May 17th 2021

Brian I. Rini, MD, discusses the results of an exploratory analysis of the phase 3 IMmotion151 trial in metastatic renal cell carcinoma.

Dr. Rini on the Mechanism of Action of Tivozanib in Relapsed/Refractory RCC

April 26th 2021

Brian I. Rini, MD, discusses the mechanism of action of tivozanib in relapsed/refractory renal cell carcinoma.

Dr. Rini on Choosing Between IO/IO or IO/TKI Combinations in mRCC

November 6th 2020

Brian I. Rini, MD, discusses choosing between combinations of dual immunotherapy and immunotherapy/VEGF TKIs in metastatic renal cell carcinoma.

Dr. Rini on Challenges With Biomarkers in RCC

September 24th 2019

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses challenges with biomarkers in renal cell carcinoma (RCC).

Dr. Rini on Managing the Toxicity of Pembrolizumab Plus Axitinib in mRCC

May 23rd 2019

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses managing the toxicity of pembrolizumab plus axitinib in patients with metastatic renal cell carcinoma.

Dr. Rini Discusses Pembrolizumab Plus Axitinib in mRCC

April 24th 2019

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the combination of pembrolizumab plus axitinib in the treatment of patients with metastatic renal cell carcinoma.

Dr. Rini Discusses Tivozanib in Advanced RCC

March 2nd 2019

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the potential for tivozanib in patients with advanced renal cell carcinoma.

Dr. Rini on Molecular Characteristics of the IMmotion151 Study in RCC

November 7th 2018

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the molecular characteristics of patients with renal cell carcinoma (RCC) enrolled on the IMmotion151 study.

Dr. Rini on the Tolerability of Atezolizumab Plus Bevacizumab in RCC

July 3rd 2018

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the tolerability of atezolizumab (Tecentriq) plus bevacizumab (Avastin) in renal cell carcinoma.

Dr. Rini Discusses Atezolizumab Plus Bevacizumab in RCC

June 20th 2018

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses atezolizumab (Tecentriq) plus bevacizumab (Avastin) in renal cell carcinoma.

Dr. Rini Discusses the Findings of IMmotion151 in RCC

June 12th 2018

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses findings from the IMmotion151 trial in renal cell carcinoma.

Dr. Rini on the Efficacy of Axitinib and Pembrolizumab in RCC

August 4th 2017

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the efficacy of pembrolizumab (Keytruda) and axitinib (Inlyta) combined in patients with renal cell carcinoma (RCC).

Dr. Rini on Sequencing of Immunotherapy Combinations in RCC

July 21st 2017

Brian I. Rini, MD, professor of Medicine, Cleveland Clinic, discusses sequencing of immunotherapy combinations for patients with renal cell carcinoma (RCC).

Dr. Rini on Adjuvant Immunotherapy in Renal Cell Carcinoma

July 6th 2017

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the potential of immunotherapy as an adjuvant treatment for patients with renal cell carcinoma (RCC).

Dr. Rini on Pembrolizumab Plus Axitinib in RCC

June 14th 2017

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses a phase I study of pembrolizumab (Keytruda) plus axitinib (Inlyta) in patients with renal cell carcinoma (RCC).

Dr. Rini on Axitinib for Treatment of Metastatic Renal Cell Carcinoma

October 19th 2015

Brian Rini, MD, associate professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, discusses a phase Il study that examined axitinib as a second-line therapy for metastatic renal cell carcinoma.

Rini Discusses Variable Impact of Angiogenesis in Solid Tumors

October 13th 2014

Rini, who is a professor at the Cleveland Clinic Lerner College of Medicine in addition to holding several posts at the Case Comprehensive Cancer Center, discussed broad issues in antiangiogenic research in this interview with OncologyLive.

Dr. Rini on Cytoreductive Nephrectomy in RCC

May 7th 2014

Brian Rini, MD, associate professor, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, discusses the role of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma (RCC).

Dr. Rini on Barriers to Optimal Care of RCC

February 14th 2014

Brian Rini, MD, associate professor, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, discusses professional practice gaps and barriers to optimal care of renal cell carcinoma (RCC).

Dr. Rini Discusses the VEGF Targeted Agent Axitinib

November 17th 2011

Dr. Brian I. Rini from the Cleveland Clinic Discusses the VEGF Targeted Agent Axitinib